The study found new targets for the treatment of triple negative breast cancer

The Research Group of the Shanghai Institute of Life Sciences (Institute of Nutrition and Health) of the Chinese Academy of Sciences analyzed the transcription group characteristics of patients with triple negative breast cancer (TNBC) and found and confirmed the new inhibitor Wwox protein of JAK2/STAT3 signal in breast cancer, and clarified that the negative correlation between the abnormal weakening of Wwox and the abnormal activation of JAK2/STAT3 is an important reason for the transfer of highly malignant TNBC. The results of the study were published online
.
recent years, the incidence of breast cancer in China continues to rise, TNBC is one of the more malignant types, its invasive, distant transfer risk is large, the prognosmation is very poor. At present, its treatment method is relatively single, mainly chemotherapy, easy to relapse and metastasis. Endocrine therapy and molecular targeting were ineffective for TNBC compared to other types of breast cancer.
The team screened TNBC cells for transcriptional histological analysis of normal breast cells and obtained abnormal expression characteristics of multiple signals in the IL6/JAK2/STAT3 path, proving that the highly abnormal expression of IL6 in TNBC cells and the continued activation of JAK2/STAT3, which is activated, may be an important factor in TNBC's long-range metastasis. The study also found that SOCS3, the main inhibitor previously thought to be JAK2/STAT3, did not play a role in TNBC, while the newly discovered brittle site gene Wwox produced specific inhibitions during the continuous activeization of the IL6/JAK2/STAT3 signal path in breast cancer. The researchers verified Wwox's inhibition of persistent STAT3 signal high phosphorylation levels and continuous active state in the body. Wwox has been shown to be located at a common brittle location (CFSs) in the human genome, and CFSs are prone to breakage, affecting the coding of related functional genes. The researchers' studies, based on in vitro and clinical evidence, showed that Wwox had significantly lower expression on TNBC than other types of breast cancer and had a negative correlation with the continued activeness of IL6/JAK2/STAT3 abnormalities. The study is the first to demonstrate Wwox's strong inhibition of tumor cell JAK2/STAT3 high phosphorylation and continuous activity, and Wwox's mechanism of action is expected to provide targets and clues for TNBC's individualized therapy. (Source: China Science News)